Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Ritchie

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Leukemia & Lymphoma|October 25, 2008
Is allogeneic stem cell transplantation for transformed follicular lymphoma anti-lymphoma stem cell therapy?David S Ritchie
Blood|March 7, 2024
The brain may devise laws for the bloodDavid S Ritchie
Leukemia & Lymphoma|October 6, 2007
Plasma cell lysate as an antigen source in multiple myeloma immunotherapyDavid S Ritchie
Leukemia & Lymphoma|May 10, 2007
The role of second autografts in the treatment of Hodgkin lymphomaDavid S Ritchie
Current Opinion in Immunology|February 19, 2014
Allogeneic transplantation as anticancer immunotherapySimrit Parmar, David S Ritchie
Leukemia & Lymphoma|March 29, 2011
The Goldilocks conundrum: how much granulocyte colony-stimulating factor following autologous stem cell transplant is 'just right'?Kirsten Herbert, David S Ritchie
Cell|July 28, 2009
A new therapeutic target for leukemia comes to the surfaceDavid S Ritchie, Mark J Smyth
Nature Reviews. Immunology|August 9, 2014
Natural killer T cells: drivers or passengers in preventing human disease?Stuart P Berzins, David S Ritchie
Leukemia & Lymphoma|August 9, 2020
Poor graft function, a significant and emerging clinical challenge post allogeneic stem cell transplantationAshvind A Prabahran, David S Ritchie
Blood|March 27, 2010
B cells in GVHD: friend or foe?Joanne E Davis, David S Ritchie
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|October 25, 2008
Is allogeneic stem cell transplantation for transformed follicular lymphoma anti-lymphoma stem cell therapy?David S Ritchie
Blood|March 7, 2024
The brain may devise laws for the bloodDavid S Ritchie
Leukemia & Lymphoma|October 6, 2007
Plasma cell lysate as an antigen source in multiple myeloma immunotherapyDavid S Ritchie
Leukemia & Lymphoma|May 10, 2007
The role of second autografts in the treatment of Hodgkin lymphomaDavid S Ritchie
Current Opinion in Immunology|February 19, 2014
Allogeneic transplantation as anticancer immunotherapySimrit Parmar, David S Ritchie
Leukemia & Lymphoma|March 29, 2011
The Goldilocks conundrum: how much granulocyte colony-stimulating factor following autologous stem cell transplant is 'just right'?Kirsten Herbert, David S Ritchie
Cell|July 28, 2009
A new therapeutic target for leukemia comes to the surfaceDavid S Ritchie, Mark J Smyth
Nature Reviews. Immunology|August 9, 2014
Natural killer T cells: drivers or passengers in preventing human disease?Stuart P Berzins, David S Ritchie
Leukemia & Lymphoma|August 9, 2020
Poor graft function, a significant and emerging clinical challenge post allogeneic stem cell transplantationAshvind A Prabahran, David S Ritchie
Blood|March 27, 2010
B cells in GVHD: friend or foe?Joanne E Davis, David S Ritchie
Pageof 10